Liver function tests (LFTs) are regularly included in screening blood panels, making them among the most frequently requested laboratory tests in clinical practice [1–3]. Their widespread use and automation have led to frequent detection of abnormal results, even in asymptomatic individuals. For instance, a United States population-based study (1999–2002) reported increased activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in 8.9 % and 4.9 %, respectively [4]. Similarly, data from the University Hospital Birmingham Foundation Trust revealed that one-third of the LFTs requests in 2016 included at least one abnormal result [3].
